Kura Oncology Stock News

Equities analysts expect that Kura Oncology Inc (NASDAQ:KURA) will post earnings per share of ($0.42) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for

DUBLIN--(BUSINESS WIRE)--The "Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019" drug pipelines have been added to ResearchAndMarkets.com's offering. Summary According to the recently publ

Kura Oncology (NASDAQ:KURA) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Saturday, BidAskClub reports. KURA has been the

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annu

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Admini

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).

SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

During the Lightning Round segment of Mad Money Friday night one caller inquired about Kura Oncology : "This has personalized cancer treatments and I like it for speculation," said Jim Cramer. In th

Q3 2019 Kura Oncology Inc Earnings Call

SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and thes

SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.